Current Report Filing (8-k)
June 03 2021 - 6:03AM
Edgar (US Regulatory)
0001082554
false
0001082554
2021-06-03
2021-06-03
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15 (d) of
the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 3, 2021
United Therapeutics Corporation
(Exact Name of Registrant as Specified in
its Charter)
Delaware
|
|
000-26301
|
|
52-1984749
|
(State or Other
|
|
(Commission
|
|
(I.R.S. Employer
|
Jurisdiction of
|
|
File Number)
|
|
Identification Number)
|
Incorporation)
|
|
|
|
|
1040 Spring Street
|
|
|
Silver Spring, MD
|
|
20910
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (301) 608-9292
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant
to Section 12(b) of the Act:
Title of each class
|
|
Trading symbol(s)
|
|
Name of each exchange on which
registered
|
Common Stock, par value $0.01 per share
|
|
UTHR
|
|
Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ¨
Item 8.01. Other Events.
On June 3, 2021, United Therapeutics Corporation issued a press release
announcing the dosing of the first patient in the pivotal TETON study of Tyvaso® (treprostinil) Inhalation Solution
in idiopathic pulmonary fibrosis. The press release is attached as Exhibit 99.1 and is incorporated herein by reference.
TYVASO is a
registered trademark of United Therapeutics Corporation.
Item 9.01. Exhibits
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
UNITED THERAPEUTICS CORPORATION
|
|
|
|
Dated: June 3, 2021
|
By:
|
/s/ Paul A. Mahon
|
|
Name:
|
Paul A. Mahon
|
|
Title:
|
General Counsel
|
United Therapeutics (NASDAQ:UTHR)
Historical Stock Chart
From Aug 2024 to Sep 2024
United Therapeutics (NASDAQ:UTHR)
Historical Stock Chart
From Sep 2023 to Sep 2024